6.5 C
New York
Wednesday, May 25, 2022

WHO calls for increased production of dexamethasone to treat severe forms of COVID-19

Must Read

New Research Identifies Genetic Origins of 3 Mitochondrial Diseases

Mitochondrial diseases are a set of rare hereditary disorders affecting one in every 4,300 individuals. It is...

AI Reveals New Math Behind The Search For Exoplanets

AI Reveals New Math Behind The Search For Exoplanets New planets orbiting other stars...

Iron In Meteorites Indicates A More Chaotic Early Solar System – New Research

Planetary scientists have more precisely reconstructed the early history of many asteroids than ever before, indicating that...
Manish Saini
Manish works as a Journalist and writer at Revyuh.com. He has studied Political Science and graduated from Delhi University. He is a Political engineer, fascinated by politics, and traditional businesses. He is also attached to many NGO's in the country and helping poor children to get the basic education. Email: Manish (at) revyuh (dot) com

The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, called for increased production of dexamethasone to treat critically ill patients with COVID-19.

“Although the data is preliminary, recent studies, showing that the steroid drug dexamethasone has the potential to save the lives of critically ill patients with COVID-19, give us reason to celebrate. The next challenge is to increase production and distribute dexamethasone rapidly and equitably around the world, with a focus on where it is most needed,” said Ghebreyesus.

According to the WHO chief, the demand for the drug is already outstripping the supply following successful trials in the UK.

“Luckily, that drug is not expensive and there are many dexamethasone producers around the world who are sure they can increase production,” added Ghebreyesus.

On June 16, Ghebreyesus called the first results of clinical trials of dexamethasone against COVID-19 in the United Kingdom a “scientific advance.”

According to the study carried out by the University of Oxford, this corticosteroid, normally used as an anti-inflammatory, reduces the risk of death in ventilator-connected patients by 35%, and that of patients receiving treatment with 20%. oxygen.

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -